Fosaprepitant
- Generic Name
- Fosaprepitant
- Brand Names
- Emend, Focinvez, Ivemend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22F7N4O6P
- CAS Number
- 172673-20-0
- Unique Ingredient Identifier
- 6L8OF9XRDC
- Background
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
- Indication
Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and vomiting with initial and repeat courses of moderately emetogenic cancer chemotherapy.
- Associated Conditions
- Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
- Conditions
- Nausea and VomitingNauseaVomiting
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 212
- Registration Number
- NCT06740812
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects
- Conditions
- Bioavailability
- Interventions
- Drug: BH006 for injection
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06427681
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
- Conditions
- NauseaNausea and VomitingVomiting
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 250
- Registration Number
- NCT06382012
- Locations
- 🇺🇸
Montefiore Medical Center (Montefiore and Weiler EDs), Bronx, New York, United States
Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery
- Conditions
- Postoperative Nausea and VomitingThoracic DiseasesAnesthesia Complication
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 234
- Registration Number
- NCT05881486
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- Conditions
- Chemotherapy-induced Nausea and VomitingBreast Cancer
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 1028
- Registration Number
- NCT05841849
- Locations
- 🇨🇳
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang, China
Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention
- Conditions
- Postoperative Nausea and VomitingGynecologic Surgical ProceduresLaparoscopy
- Interventions
- Drug: normal saline
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 144
- Registration Number
- NCT05773950
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT05755659
- Locations
- 🇨🇳
The First Affiliated Hospital of Air Force Military Medical University, Xi'an, Shaanxi, China
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
- Conditions
- Cervical CancerNasopharyngeal CancerChemotherapy-induced Nausea and VomitingRadiation-Induced Nausea and VomitingAntiemetic
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Shantou University Medical College
- Target Recruit Count
- 116
- Registration Number
- NCT05564286
- Locations
- 🇨🇳
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
- Conditions
- Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
- Interventions
- Drug: HR20013 for injection；dexamethasone
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 754
- Registration Number
- NCT05509634
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center Yuexiu Campus, Guangzhou, Guangdong, China
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
- Conditions
- Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients
- Interventions
- Drug: Placebo(normal saline)
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Shanghai Children's Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT05230654
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.